Colon Cancer Risk Cut by Aspirin and NSAIDs Save

A population-based study from Northern Denmark studied the effects of aspirin and NSAIDs on colorectal cancer rates (Citation source http://buff.ly/1KJQ6H3).

Among 10280 case patients and 102800 control participants, the use of 75 to 150 mg of aspirin continuously for five years or longer was associated with a 27 percent reduced risk for colorectal cancer and five or more years of continuous nonaspirin NSAID use was associated with a 30 to 45 percent reduction in colorectal cancer risk. Nonaspirin NSAIDS with the highest COX-2 selectivity were associated with the largest risk reductions.

Colorectal cancer is the third most common non-skin cancer in the world. According to the CDC, in 2012, 134,784 people in the US were diagnosed with colorectal cancer and 51,516 died from colorectal cancer.  These findings suggest an important role for NSAIDs in colorectal cancer prevention strategies.